Investor
B Group, Inc.
CIK 0002043476 · filed 2026-02-17 · SEC filing
13F book
$135.4M
Positions
15
Largest name
33.1%
Adma Biologics, Inc. · ADMA
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Adma Biologics, Inc. | ADMA | 2.46M | $44.8M | 33.1% | — | Held |
| Cellectis S.A. | CLLS | 3.28M | $15.9M | 11.7% | — | Held |
| Palisade Bio, Inc. | PALI | 4.5M | $10.6M | 7.8% | — | Held |
| Taysha Gene Therapies, Inc. | TSHA | 1.8M | $9.9M | 7.3% | — | Held |
| Praxis Precision Medicines I | — | 33.2K | $9.8M | 7.2% | — | Held |
| Sight Sciences, Inc. | SGHT | 920K | $7.3M | 5.4% | — | Held |
| Zai Lab Ltd | ZLAB | 400K | $7.06M | 5.2% | — | Held |
| Structure Therapeutics Inc. | GPCR | 90K | $6.26M | 4.6% | — | Held |
| Assembly Biosciences, Inc. | ASMB | 175.7K | $5.98M | 4.4% | — | Held |
| Iovance Biotherapeutics, Inc. | IOVA | 1.5M | $4.09M | 3.0% | — | Held |
| Spyre Therapeutics, Inc. | SYRE | 100K | $3.28M | 2.4% | — | Held |
| Aura Biosciences, Inc. | AURA | 572.6K | $3.12M | 2.3% | — | Held |
| Ultragenyx Pharmaceutical In | — | 135K | $3.1M | 2.3% | — | Held |
| Oruka Therapeutics, Inc. | ORKA | 75K | $2.27M | 1.7% | — | Held |
| Apogee Therapeutics, Inc. | APGE | 20K | $1.51M | 1.1% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.